This study did not find any clinically significant change in serum markers of renal function in the one month after intravitreal ranibizumab or aflibercept. It did, however, find a non-significant rise in creatinine with aflibercept, that was not seen with ranibizumab.
|Number of pages||3|
|Journal||Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association|
|Early online date||10 Feb 2023|
|Publication status||Published - 30 Jun 2023|